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Background
Tumor infiltrating lymphocytes (TILs) are a significant
component of the tumor microenvironment [1]. In
breast cancer the prognostic and predictive value of TIL
is under active investigation [2]. The goal of our study
was to define specific TIL subtypes and regional quanti-
fication in breast cancer of patients from the MENA
region.
Methodology
47 FFPE samples with known clinic-pathological data
were selected and studied using immunohistochemistry
technique. TIL immune markers studied were CD3,
CD8, CD45RO and FOXP3 and quantified by modified
H-score system. Results were analyzed via SPSS.
Results
A positive correlation between CD3 and CD8 expression
(rs=0.614, n=24, P 0.001) and CD3 and CD45RO
expression (rs=0.621, n=24, P 0.001) were noted in the
center of the tumor (CT).CD3 median percentage in CT
was higher in grade 2 and grade 3 breast carcinoma
compared to grade 1 (P 0.023). CD3 in the center of the
tumor and CD8 in the invasive margins (IM) were sig-
nificantly higher in ER/PR negative Her2/neu positive
tumors compared to triple negative breast cancers.
Lower CD3, CD8 and FOXP3 percentages were noticed
in TNBC tumors. CD45RO median percentage was
shown to be higher in the IM region.
Conclusion
TIL were affected by the patient clinic-pathological
characteristics.
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